4.4 Article

Continuous Glucose Monitor Use Prevents Glycemic Deterioration in Insulin-Treated Patients with Type 2 Diabetes

Journal

DIABETES TECHNOLOGY & THERAPEUTICS
Volume 24, Issue 5, Pages 332-337

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2021.0450

Keywords

Continuous glucose monitors; Self-monitoring of blood glucose; Type 2 diabetes; Glycemic control; Hypoglycemia; Real-world evidence

Funding

  1. Dexcom [R01DK103721]
  2. NIH [P30 DK092924]
  3. NIDDK
  4. Kaiser Permanente Northern California Community Health

Ask authors/readers for more resources

CGM may help prevent glycemic deterioration in well-controlled patients with insulin-treated T2D.
Continuous glucose monitoring (CGM) is indicated in poorly controlled insulin-treated patients with type 2 diabetes (T2D) to improve glycemic control and reduce the risk of hypoglycemia, but the benefits of CGM for lower risk patients have not been well studied. Among 17,422 insulin-treated patients with T2D with hemoglobin A1c (HbA1c) <8% and no recent severe hypoglycemia (based on emergency room visits or hospitalizations), CGM initiation occurred in 149 patients (17,273 noninitiators served as reference). Changes in HbA1c and severe hypoglycemia rates for the 12 months before and after CGM initiation were calculated. CGM initiation was associated with decreased HbA1c (-0.06%), whereas noninitiation was associated with increased HbA1c (+0.32%); a weighted adjusted difference-in-difference model of change in HbA1c yielded a net benefit of -0.30%; 95% CI -0.50%, -0.10%; P = 0.004). No significant differences were observed for severe hypoglycemia. CGM may be useful in preventing glycemic deterioration in well-controlled patients with insulin-treated T2D.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available